Try our beta test site
IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more...
Trial record 1 of 1 for:    VX-150
Previous Study | Return to List | Next Study

A Study of the Efficacy and Safety of VX-150 in Subjects With Osteoarthritis of the Knee

This study has been completed.
Sponsor:
Information provided by (Responsible Party):
Vertex Pharmaceuticals Incorporated
ClinicalTrials.gov Identifier:
NCT02660424
First received: December 18, 2015
Last updated: October 3, 2016
Last verified: September 2016
  Purpose
The Primary objective of this study is to evaluate the efficacy of VX-150 in the treatment of osteoarthritis pain

Condition Intervention Phase
Osteoarthritis
Drug: VX-150
Drug: Placebo
Phase 2

Study Type: Interventional
Study Design: Allocation: Randomized
Intervention Model: Crossover Assignment
Masking: Double Blind (Participant, Investigator)
Primary Purpose: Treatment
Official Title: A Phase 2a Randomized, Double-blind, Placebo-Controlled, Crossover Study of the Efficacy and Safety of VX-150 in Subjects With Osteoarthritis of the Knee

Resource links provided by NLM:


Further study details as provided by Vertex Pharmaceuticals Incorporated:

Primary Outcome Measures:
  • Change from baseline in Western Ontario and McMaster Universities (WOMAC) osteoarthritis index pain subscale score at Day 14 [ Time Frame: from baseline at Day 14 ]

Secondary Outcome Measures:
  • Proportion of subjects with ≥50% reduction in WOMAC pain subscale at Day 14 [ Time Frame: at Day 14 ]
  • Change from baseline in total WOMAC score at Day 14 [ Time Frame: at Day 14 ]
  • Use of rescue medications [to be obtained by electronic diary and questionnaire] [ Time Frame: Treatment periods1 (14 days) and 2 (14 days) ]
  • Safety and tolerability based on the incidence and type of adverse events (AEs),changes from baseline in clinically significant laboratory test results, and assessment of 12 lead electrocardiograms (ECGs) and vital signs at designated visits. [ Time Frame: up to 12 weeks (duration of study) ]
  • Plasma PK parameters of prodrug, VX-150 and its primary metabolite: Cmax [maximum plasma concentrations] [ Time Frame: Days 1,14 of each treatment periods ]
  • Plasma PK parameters of prodrug, VX-150 and its primary metabolite: Tmax [time to maximum plasma concentration] [ Time Frame: Days 1,14 of each treatment periods ]
  • Plasma PK parameters of prodrug, VX-150 and its primary metabolite: AUC [area under the plasma concentration-time curve] [ Time Frame: Days 1,14,16,18 of each treatment periods ]

Enrollment: 124
Study Start Date: December 2015
Study Completion Date: September 2016
Primary Completion Date: August 2016 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: VX-150, placebo
Sequence 1: VX-150 in Treatment Period 1→washout→ placebo in Treatment Period 2
Drug: VX-150 Drug: Placebo
Experimental: placebo, VX-150
Sequence 2: placebo in Treatment Period 1→washout→ VX-150 in Treatment Period 2
Drug: VX-150 Drug: Placebo

  Eligibility

Ages Eligible for Study:   40 Years to 80 Years   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Willing and able to comply with scheduled visits, treatment plan, study restrictions, laboratory tests, contraceptive guidelines, and other study procedures.
  • Subjects (male and female [of non-childbearing potential]) will be between the ages of 40 and 80 years, inclusive. Female subjects must have a negative pregnancy test at Screening and on Day 1 of each Treatment Period and must not be nursing; male subjects must not have a female partner who is pregnant or nursing.
  • Body mass index (BMI) of 18.0 to 38.0 kg/m2, inclusive, and a total body weight of 50 to 150 kg.
  • Ambulatory with osteoarthritis of the knee with symptoms for at least 6 months and pain on the majority of days for the past 30 days. Symptoms must include knee joint pain. In subjects with bilateral knee osteoarthritis, the more symptomatic knee will be considered the index knee.
  • Radiographic evidence of at least one tibiofemoral osteophyte in the index knee within 12 months before the Day 1 Visit.
  • WOMAC pain subscale score

Exclusion Criteria:

  • History in the past 10 years of reactive arthritis, rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis, arthritis associated with inflammatory bowel disease, sarcoidosis, amyloidosis or fibromyalgia.
  • History in the past 10 years of malignancy with the exception of resected basal cell carcinoma, squamous cell carcinoma of the skin or resected cervical atypia or carcinoma in situ.
  • History of cardiac dysrhythmias requiring anti-arrythmia treatment(s).
  • History of abnormal laboratory results ≥2.5 × upper limit of normal (ULN) indicative of any significant medical disease which in the opinion of the investigator would preclude the subjects participation in the study.
  • A known or clinically suspected infection with human immunodeficiency virus or hepatitis B or C viruses.
  • Other serious, acute or chronic medical or psychiatric illness that in the judgment of the investigator could compromise subject safety, limit the subject's ability to complete the study and/or compromise the objectives of the study.
  • Either participated within 3 months in another investigational study in which the subject was exposed to study drugs or vaccines,or will participate concurrently in such study.
  • History of drug or alcohol dependence in the past 3 years, or a positive test for drugs of abuse at the Screening Visit.
  • Requires opioids for pain relief.
  • Changed analgesic treatment regimen within 30 days of the Screening Visit.
  • Received or plan to receive short acting hyaluronic acid, corticosteroid, or other intra-articular injections as follows:

    1. in the index knee within 3 months of the Screening Visit, or at any time during the study
    2. in any other joint within 4 weeks of the Screening Visit, or at any time during the study
  • Received or plan to receive long acting hyaluronic acid or other intra-articular injections as follows:

    1. in the index knee within 6 months of the Screening Visit, or at any time during the study
    2. in any other joint within 4 weeks of the Screening Visit, or at any time during the study
  • History of arthroscopic or open surgery within 12 months before the Screening Visit, or have a planned surgery during, or immediately after, study follow-up.
  • History of joint replacement surgery in the index knee.
  • Significant hip pain, ipsilateral to the index knee that may interfere with assessments of index knee pain.
  • Clinical signs and symptoms of an active knee infection.
  • Current use of a handicap assistance device (unilateral assistance device such as a cane is permitted).
  • Started a new physical therapy, weight loss, or exercise program within 3 months of the Screening Visit, or are not willing to maintain a stable program during the course of the study.
  • Lab abnormalities at the screening visit.
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT02660424

Locations
United States, California
San Diego, California, United States
United States, Florida
West Palm Beach, Florida, United States
United States, Georgia
Marietta, Georgia, United States
United States, Indiana
Valparaiso, Indiana, United States
United States, Kansas
Wichita, Kansas, United States
United States, Michigan
Bay City, Michigan, United States
United States, Nevada
Las Vegas, Nevada, United States
United States, New York
Hartsdale, New York, United States
United States, Pennsylvania
Duncansville, Pennsylvania, United States
United States, Rhode Island
Providence, Rhode Island, United States
United States, Tennessee
Chattanooga, Tennessee, United States
United States, Virginia
Danville, Virginia, United States
Sponsors and Collaborators
Vertex Pharmaceuticals Incorporated
  More Information

Responsible Party: Vertex Pharmaceuticals Incorporated
ClinicalTrials.gov Identifier: NCT02660424     History of Changes
Other Study ID Numbers: VX15-150-101
Study First Received: December 18, 2015
Last Updated: October 3, 2016

Additional relevant MeSH terms:
Osteoarthritis
Osteoarthritis, Knee
Arthritis
Joint Diseases
Musculoskeletal Diseases
Rheumatic Diseases

ClinicalTrials.gov processed this record on April 27, 2017